LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company, has announced its participation in the upcoming DealFlow Discovery Conference on January 28-29, 2026, in Atlantic City, New Jersey. The company’s Chief Executive Officer, Geordan Pursglove, will hold one-on-one meetings with investors throughout the event at The Borgata Hotel, Casino & Spa. Interested parties can register for the conference and schedule meetings via the official conference website.

LIXTE is primarily focused on advancing its lead compound, LB-100, which functions as a first-in-class inhibitor of protein phosphatase 2A (PP2A). This innovative therapy has shown promise in clinical trials for various cancers, including Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. LIXTE’s research indicates that LB-100 is well-tolerated in cancer patients at doses correlated with anti-cancer efficacy, positioning it as a significant player in the realm of cancer treatments. The therapeutic strategy is based on the emerging concept of “activation lethality,” which aims to reshape conventional cancer treatment paradigms.

In addition to its core oncology initiatives, LIXTE's subsidiary, Liora Technologies Europe Ltd., is making strides in proton therapy development. The flagship LiGHT System promises meaningful advancements in treating tumors via electronically controlled proton therapy, showcasing LIXTE's commitment to innovation across different treatment modalities.

With a robust patent portfolio securing its groundbreaking research, LIXTE continues its mission to develop and commercialize new cancer therapies that could vastly improve patient outcomes. For more details on LIXTE or to engage with company representatives, stakeholders are encouraged to visit their website or contact their investor relations team.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) is making notable strides in the pharmaceutical sector with its innovative drug candidate, LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A). With its participation at the DealFlow Discovery Conference on January 28-29, 2026, there’s an opportunity for investors to engage directly with LIXTE's leadership. This could catalyze interest in the stock, especially in light of the promising developments in LIXTE's clinical trials.

LB-100 has exhibited a favorable safety profile and demonstrates potential efficacy as an enhancer of existing cancer therapies, including chemotherapy and immunotherapy. This unique approach within the emerging field of activation lethality positions LIXTE strategically in a competitive oncology market, providing a potential edge in treatment paradigms. Laws protecting LIXTE's intellectual property bolster its prospects, potentially leading to a competitive market position should LB-100 receive regulatory approval.

Currently, LIXTE is undertaking proof-of-concept trials for several challenging cancers, including Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. Such efforts not only signal the company's commitment to innovation but could greatly expand its market share in oncology if successful. Investors should keep an eye on clinical trial updates which may significantly influence stock performance.

Additionally, LIXTE’s move to develop electronically controlled proton therapy systems through its subsidiary, Liora Technologies, adds another dimension to its portfolio, presenting further growth avenues and risk diversification.

As LIXTE engages with potential investors at the conference, it presents a unique opportunity for stakeholders to gauge the company’s strategic direction and capitalize on potential volatility within the stock. For current and prospective investors, it is advisable to monitor ongoing clinical trial results and initiate dialogue with LIXTE’s management for deeper insights into its forward strategy.